Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 22,562 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $28.31, for a total transaction of $638,730.22. Following the completion of the transaction, the chief executive officer directly owned 436,280 shares of the company’s stock, valued at approximately $12,351,086.80. The trade was a 4.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Friday, July 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $27.75, for a total value of $626,095.50.
• On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The stock was sold at an average price of $35.00, for a total value of $1,361,500.00.
• On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.50, for a total value of $643,017.00.

Heartflow Stock Up 1.0%

Shares of NASDAQ HTFL opened at $29.85 on Thursday. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22. The business has a 50 day moving average price of $28.76 and a two-hundred day moving average price of $27.70. The firm has a market cap of $2.57 billion and a PE ratio of -9.60.

Heartflow (NASDAQ:HTFL) last announced its earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The business had revenue of $52.59 million during the quarter. The company’s revenue for the quarter was up 41.3% compared to the same quarter last year. On average, analysts anticipate that Heartflow, Inc. will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Heartflow

Large investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Heartflow during the fourth quarter worth $27,000. Russell Investments Group Ltd. acquired a new position in shares of Heartflow in the 4th quarter valued at about $45,000. Legal & General Group Plc bought a new stake in shares of Heartflow during the 3rd quarter valued at about $59,000. Essential Partners LLC bought a new stake in shares of Heartflow during the 1st quarter valued at about $57,000. Finally, Strs Ohio acquired a new stake in Heartflow during the fourth quarter worth about $99,000.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on HTFL shares. Robert W. Baird assumed coverage on shares of Heartflow in a report on Friday, July 31st. They issued an “outperform” rating and a $34.00 price target on the stock. Stifel Nicolaus set a $40.00 target price on shares of Heartflow in a research report on Wednesday, July 15th. Wells Fargo & Company upped their target price on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Piper Sandler reaffirmed an “overweight” rating on shares of Heartflow in a research report on Thursday, June 11th. Finally, Canaccord Genuity Group decreased their price target on Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Heartflow currently has an average rating of “Moderate Buy” and an average price target of $36.57.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.